Somaxon Pharmaceuticals to Present at the BMO Capital Markets 10th Annual ... - MarketWatch (press release)
Somaxon Pharmaceuticals to Present at the BMO Capital Markets 10th Annual .
Phase 3 Clinical Trial Data for Somaxon Pharmaceuticals' Insomnia Drug to Be ... - Sleep Review
Phase 3 Clinical Trial Data for Somaxon Pharmaceuticals' Insomnia Drug to Be .
Somaxon Pharmaceuticals Announces Acceptance of Phase 3 Clinical Trial Data ... - MarketWatch (press release)
Somaxon Pharmaceuticals Announces Acceptance of Phase 3 Clinical Trial Data .
NASDAQ bulls on run: (APCVZ, SATC, ESLR, SOMX, NVAX) - Penny Stock Live (blog)
NASDAQ bulls on run: (APCVZ, SATC, ESLR, SOMX, NVAX)Penny Stock Live (blog)On March 18, 2010, the food and drug administration (FDA) notified the Company that it approved its New Drug Application (NDA) for Silenor (doxepin) three .
Somaxon Pharmaceuticals Establishes Silenor Commercial Team - MarketWatch (press release)
Somaxon Pharmaceuticals Establishes Silenor Commercial TeamMarketWatch (press release)Silenor is a low-dose (3 mg, 6 mg) oral tablet formulation of doxepin that is patent protected for use in insomnia.